Announcements Trials
Browse Landscape

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2352Neoplasms 1707Prostatic Neoplasms 1197Lung Neoplasms 923Colorectal Neoplasms 882Carcinoma, Non-Small-Cell Lung 867Leukemia, Myeloid, Acute 593Pancreatic Neoplasms 577Multiple Myeloma 549Carcinoma, Hepatocellular 516Brain Neoplasms 513Neoplasm Metastasis 459Head and Neck Neoplasms 454Melanoma 414Ovarian Neoplasms 413Glioblastoma 402Precursor Cell Lymphoblastic Leukemia-Lymphoma 400Stomach Neoplasms 375Uterine Cervical Neoplasms 365Squamous Cell Carcinoma of Head and Neck 361Rectal Neoplasms 341Recurrence 336Sarcoma 325Hematologic Neoplasms 323Colonic Neoplasms 323Lymphoma 319Triple Negative Breast Neoplasms 291Carcinoma, Renal Cell 283Urinary Bladder Neoplasms 281Glioma 278

Interventions

trastuzumab deruxtecan 1Isovaleryl-CoA Dehydrogenase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × HER2 Overexpression × 1 year × Clear all
NCT07035353 2025-06-25

A Real-world Clinical Study of T-DXd for the Treatment of Chinese Patients With HER2 Overexpressing and HER2 Underexpressing Advanced Breast Cancer

Tianjin Medical University Cancer Institute and Hospital

Not yet recruiting
200 enrolled
Breast

HER2 Overexpression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡